At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 65 enrolled
Drug / intervention
empagliflozin 10mg +2 moredrug
Likely dose
empagliflozin 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 52-week Randomised, Double-blind, Parallel Group, Safety and Efficacy Study of Empagliflozin Once Daily as add-on Therapy to Glucagon-like Peptide-1 Receptor Agonist in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control
In Brief
A Phase 4 clinical trial evaluating empagliflozin 10mg, empagliflozin 25 mg, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 65 participants across 16 sites.
Detailed Summary
This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesJapan
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartOct 2015
Primary CompletionJun 2017
TodayJul 2026
First PostedOct 28, 2015
Enrollment StartOct 29, 2015
Primary CompletionJun 2, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 10.7 years ago
Interventions
empagliflozin 10mgdrug
empagliflozin 25 mgdrug
Placebodrug
For blinding purposes